{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:07:28Z","timestamp":1794474448449,"version":"4.9.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the long-term effectiveness of the combination of Iguratimod (IGU) and Alendronate for patients with Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) syndrome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A prospective cohort study was conducted on patients diagnosed with SAPHO syndrome at Peking University Third Hospital and Beijing Jishuitan Hospital from 2017 to 2024. The initial treatment regimen comprised a combination of IGU and Alendronate. Patients who were followed up for &amp;gt;2\u2009years were included in our study. We collected demographic data, clinical symptoms, recurrence rates, treatment duration and overall response to therapy for all patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventeen patients were recruited for our cohort, with a median (IQR) follow-up of 2.91 (2.34) years. The mean treatment duration was 39.10\u2009months. Among patients with osteoarticular involvement (17\/17), 35.30% (6\/17) achieved complete improvement without any recurrence, 11.76% (2\/17) showed partial improvement and 52.94% (9\/17) experienced intermittent flares. For patients with skin involvement (11\/17), 63.64% (7\/11) achieved complete improvement, 27.27% (3\/11) had partial improvement and 9.09% (1\/11) experienced intermittent recurrence. Notably, 88.26% (15\/17) regained complete independence and resumed work, and 94.12% (16\/17) experienced alleviation of anxiety and insomnia. By the end of last follow-up, 52.94% (9\/17) had ceased treatment after a mean duration of 25.22\u2009months and 22.22% (2\/9) of them encountered recurrence.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The combination of IGU and Alendronate as initial treatment may be effective for the long-term management of SAPHO syndrome. \u223c41% of the patients could discontinue treatment after more than two years without recurrence.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae641","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T17:23:47Z","timestamp":1732641827000},"page":"2842-2846","source":"Crossref","is-referenced-by-count":2,"title":["Long-term effectiveness of the combination of iguratimod and alendronate in SAPHO syndrome: a prospective cohort study"],"prefix":"10.1093","volume":"64","author":[{"given":"Wangna","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Orthopedics Medicine, Beijing Jishuitan Hospital, Capital Medical University , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongji","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Medicine, Beijing Jishuitan Hospital, Capital Medical University , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueya","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Medicine, Beijing Jishuitan Hospital, Capital Medical University , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Medicine, Beijing Jishuitan Hospital, Capital Medical University , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingge","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Medicine, Beijing Jishuitan Hospital, Capital Medical University , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7206-7632","authenticated-orcid":false,"given":"Xiaoli","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Orthopedics Medicine, Beijing Jishuitan Hospital, Capital Medical University , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"2025050316135111800_keae641-B1","first-page":"187","article-title":"Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases","volume":"54","author":"Chamot","year":"1987","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"2025050316135111800_keae641-B2","doi-asserted-by":"crossref","first-page":"109018","DOI":"10.1016\/j.clim.2022.109018","article-title":"TNF-inhibitors or bisphosphonates in chronic nonbacterial osteomyelitis? - results of an international retrospective multicenter study","volume":"238","author":"Schnabel","year":"2022","journal-title":"Clin Immunol"},{"key":"2025050316135111800_keae641-B3","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s10067-020-05393-w","article-title":"Clinical characteristics of pediatric synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome: the first Chinese case series from a single center","volume":"40","author":"Wu","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025050316135111800_keae641-B4","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.semarthrit.2016.04.004","article-title":"SAPHO: treatment options including bisphosphonates","volume":"46","author":"Zwaenepoel","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025050316135111800_keae641-B5","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003688","article-title":"Treatment and monitoring of SAPHO syndrome: a systematic review","volume":"9","author":"Li","year":"2023","journal-title":"RMD Open"},{"key":"2025050316135111800_keae641-B6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10067-023-06782-7","article-title":"The clinical characteristics and prognosis of patients with SAPHO syndrome\u2014a real-world cohort study","volume":"43","author":"Duan","year":"2024","journal-title":"Clin Rheumatol"},{"key":"2025050316135111800_keae641-B7","doi-asserted-by":"crossref","first-page":"100095","DOI":"10.1016\/j.jtauto.2021.100095","article-title":"Chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO)","volume":"4","author":"Zhao","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"2025050316135111800_keae641-B8","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.clim.2015.09.013","article-title":"Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1\u03b2 expression and release","volume":"161","author":"Hofmann","year":"2015","journal-title":"Clin Immunol"},{"key":"2025050316135111800_keae641-B9","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3389\/fimmu.2019.01525","article-title":"The role of epigenetics in autoimmune\/inflammatory disease","volume":"10","author":"Surace","year":"2019","journal-title":"Front Immunol"},{"key":"2025050316135111800_keae641-B10","first-page":"457","article-title":"Propionibacterium acnes and SAPHO syndrome: a case report and literature review","volume":"25","author":"Colina","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2025050316135111800_keae641-B11","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s10067-020-05322-x","article-title":"The effectiveness of treatments for patients with SAPHO syndrome: a follow-up study of 24 cases from a single center and review of literature","volume":"40","author":"Huang","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025050316135111800_keae641-B12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11832-014-0627-7","article-title":"SAPHO syndrome: a review","volume":"9","author":"Rukavina","year":"2015","journal-title":"J Child Orthop"},{"key":"2025050316135111800_keae641-B13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fphar.2020.00073","article-title":"Iguratimod as a new drug for rheumatoid arthritis: current landscape","volume":"11","author":"Xie","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025050316135111800_keae641-B14","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/rheumatology\/keh295","article-title":"Pamidronate in the treatment of childhood SAPHO syndrome","volume":"43","author":"Kerrison","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316135111800_keae641-B15","first-page":"663","article-title":"Efficacy of bisphosphonates in patients with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a prospective open study","volume":"37","author":"Li","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025050316135111800_keae641-B16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0950-3579(94)80022-7","article-title":"The SAPHO syndrome","volume":"8","author":"Kahn","year":"1994","journal-title":"Baillieres Clin Rheumatol"},{"key":"2025050316135111800_keae641-B17","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/art.24540","article-title":"Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects","volume":"61","author":"Colina","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2025050316135111800_keae641-B18","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00296-023-05491-3","article-title":"SAPHO syndrome: current clinical, diagnostic and treatment approaches","volume":"44","author":"Demirci Yildirim","year":"2024","journal-title":"Rheumatol Int"},{"key":"2025050316135111800_keae641-B19","doi-asserted-by":"crossref","first-page":"621604","DOI":"10.3389\/fendo.2021.621604","article-title":"Sternocostoclavicular hyperostosis: positive clinical and radiological response on pamidronate","volume":"12","author":"Leerling","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025050316135111800_keae641-B20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","article-title":"From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates","volume":"75","author":"Rogers","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"2025050316135111800_keae641-B21","first-page":"157","article-title":"In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation","volume":"47","author":"De Vries","year":"1982","journal-title":"Immunology"},{"key":"2025050316135111800_keae641-B22","doi-asserted-by":"crossref","first-page":"107219","DOI":"10.1016\/j.intimp.2020.107219","article-title":"Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-\u03b1 signaling pathways","volume":"90","author":"Li","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"2025050316135111800_keae641-B23","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/rheumatology\/keg381","article-title":"Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice [J]","volume":"42","author":"Tanaka","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2025050316135111800_keae641-B24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.intimp.2016.03.038","article-title":"Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-\u03baB and MAPK pathways","volume":"35","author":"Gan","year":"2016","journal-title":"Int Immunopharmacol"},{"key":"2025050316135111800_keae641-B25","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s10067-017-3668-8","article-title":"Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis","volume":"36","author":"Wang","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025050316135111800_keae641-B26","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar2554","article-title":"T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis","volume":"10","author":"Du","year":"2008","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae641\/61007806\/keae641.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2842\/61007806\/keae641.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/5\/2842\/61007806\/keae641.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:14:11Z","timestamp":1746303251000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/5\/2842\/7908995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":26,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,11,26]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae641","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2024,11,26]]}}}